Inhibitor Therapeutics IncOTCQB:INTI
- LAST PRICE0.0740
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots0.0710/ 400
- Ask / Lots0.0800/ 200
- Open / Previous Close--- / 0.0740
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | INTI |
|---|---|---|
| 12:15 ET | 10000 | 0.0751 |
| 12:17 ET | 10000 | 0.075 |
| 01:11 ET | 29998 | 0.074 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Inhibitor Therapeutics Inc | 12.8M | -4.1x | --- |
HST Global Inc | 12.8M | -14.8x | --- |
NRX Pharmaceuticals Inc | 13.2M | -0.7x | --- |
Sensei Biotherapeutics Inc | 12.2M | -0.4x | --- |
NKGen Biotech Inc | 12.2M | -0.1x | --- |
PharmaCyte Biotech Inc | 13.4M | 3.5x | --- |
Company Information
Inhibitor Therapeutics, Inc. is a pharmaceutical development company. The Company is focused on developing and commercializing therapeutics based on already approved active pharmaceuticals that have patent-protected methods of use and/or methods of delivery for patients with certain cancers and certain non-cancerous proliferation disorders. Its primary focus is on the development of therapies initially for basal cell carcinoma (BCC), prostate and lung cancers in the United States utilizing itraconazole, a drug approved by the United States Food and Drug Administration (FDA) to treat fungal infections. The Company has developed intellectual property and know-how related to the treatment of cancer patients using itraconazole. The Company's intellectual property in the form of issued United States patents includes treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors, and treatment of lung cancer using hedgehog pathway inhibitors.
Contact Information
- Headquarters
- 4830 W. Kennedy Blvd., Suite 600TAMPA, FL, United States 33609
- Phone
- 813-766-2462
- Fax
- 813-527-0500
Executives
- Executive Chairman of the Board, Chief Executive Officer
- Francis O'Donnell
- Chief Financial Officer, Treasurer, Secretary
- James Mcnulty
- Director
- Ronald Osman
- Independent Director
- Michael Jerman
- Independent Director
- Samuel Sears
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $12.8M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 172.3M |
Inhibitor Therapeutics Inc does not pay a dividend. | |
Beta | -0.61 |
EPS | $-0.02 |
Book Value | $0.03 |
P/E Ratio | -4.1x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
